What research is being carried out for clear-cell ovarian cancer?
Clear cell ovarian cancer is probably about 10-15 per cent of what we call epithelial ovarian cancers, and again, it’s notorious for not being very sensitive to chemotherapy. It is treated commonly the same way as other ovarian cancers in the first-line setting, but if it comes back, the chances of benefit from standard chemotherapy are really very low.
There are some very interesting bits of evidence emerging for potential drugs that might work in clear-cell cancers. One is the anti-angiogenic agents, and there is a trial called NICCC which is open in the UK which is looking at an anti-angiogenic drug. It is a tablet, unlike Avastin, which is an injection, and it targets something slightly different from Avastin, even though it’s grouped in the same way. It’s called Nintedanib, and the trial is randomised between Nintedanib or standard chemotherapy.